242 related articles for article (PubMed ID: 35126102)
1. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
Blonda A; Barcina Lacosta T; Toumi M; Simoens S
Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
[No Abstract] [Full Text] [Related]
2. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
3. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
[TBL] [Abstract][Full Text] [Related]
4. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia.
Wang T; Scuffham P; Byrnes J; Downes M
J Neurol; 2022 Dec; 269(12):6544-6554. PubMed ID: 35980467
[TBL] [Abstract][Full Text] [Related]
6. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
[TBL] [Abstract][Full Text] [Related]
7. Budget Impact Analysis of Nusinersen for Spinal Muscular Atrophy in China.
Duan C; Ai D; Xu Q; Sui B; Zhao K
Value Health Reg Issues; 2023 Mar; 34():9-13. PubMed ID: 36343513
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US.
Thokala P; Stevenson M; Kumar VM; Ren S; Ellis AG; Chapman RH
Cost Eff Resour Alloc; 2020; 18():41. PubMed ID: 33041673
[TBL] [Abstract][Full Text] [Related]
9. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
[TBL] [Abstract][Full Text] [Related]
10. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis.
Shih ST; Farrar MA; Wiley V; Chambers G
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1296-1304. PubMed ID: 34321343
[TBL] [Abstract][Full Text] [Related]
11. How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.
Blonda A; Denier Y; Huys I; Simoens S
Front Pharmacol; 2021; 12():631527. PubMed ID: 34054519
[No Abstract] [Full Text] [Related]
12. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.
Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE
J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229
[TBL] [Abstract][Full Text] [Related]
13. Examining the impact of different country processes for appraising rare disease treatments: a case study analysis.
Whittal A; Nicod E; Drummond M; Facey K
Int J Technol Assess Health Care; 2021 May; 37(1):e65. PubMed ID: 34044899
[TBL] [Abstract][Full Text] [Related]
14. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
15. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
Stafinski T; Glennie J; Young A; Menon D
Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
[TBL] [Abstract][Full Text] [Related]
16. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
17. The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy.
Scheijmans FEV; Zomers ML; Fadaei S; Onrust MR; van der Graaf R; Delden JJMV; van der Pol WL; van Thiel GJMW
BMC Health Serv Res; 2022 Nov; 22(1):1320. PubMed ID: 36333803
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
Malone DC; Dean R; Arjunji R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Dabbous O
J Mark Access Health Policy; 2019; 7(1):1601484. PubMed ID: 31105909
[No Abstract] [Full Text] [Related]
19. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]